First 3 runs free, then $50/run
    First 3 runs free, then $50/run

    Impact ledger

    Vivani Medical, Inc. (VANI): the developments shaping its investment case

    Follow the evidence affecting Vivani Medical, Inc.'s valuation assumptions. Review the key developments below. Continue in Market Ontology to test your assumptions, examine related opportunities, and save the investment case you want to track.

    Research Vivani Medical, Inc. · $399/mo

    Test assumptions, examine opportunities, and save your research.

    Material developments

    2026-08-31 · 6 reports
    Novo Nordisk Advances Oral Wegovy and Implant Program Against Eli Lilly Lead
    Channel: Validation of drug delivery technology through partnership with a leading pharmaceutical company, potential for milestone payments and royalties.
    Bullish· 1-5y
    2026-08-30 · 2 reports
    Novo Nordisk Launches Oral Wegovy and Partners with Vivani for GLP-1 Implants
    Channel: Strategic partnership with a major pharmaceutical company for product development and potential commercialization, validating technology and providing funding.
    Bullish· 3-12m
    2026-08-31
    Novo Nordisk advances Wegovy pill formulation and Vivani implant partnership
    Channel: Strategic partnership with a major pharmaceutical company, validating technology and providing potential future revenue streams.
    Bullish· 3-12m

    Evidence affecting valuation assumptions

    Each entry names the assumption the evidence touches and how the evidence reads. Direction describes the business mechanism, not a stock-price conclusion.

    DateAssumptionDirectionInterpretation
    2026-07-07multipleBullishTarget re-rates to bid premium until close.

    Event impact log

    10 events mapped to VANI since 2026-08-30. Evidence through 2026-08-31.

    DateEventChannelDirectionHorizonImpact
    2026-08-31Novo Nordisk Advances Oral Wegovy and Implant Program Against Eli Lilly LeadValidation of drug delivery technology through partnership with a leading pharmaceutical company, potential for milestone payments and royalties.Bullish1-5y0.60
    2026-08-31Novo Nordisk advances Wegovy pill formulation and Vivani implant partnershipStrategic partnership with a major pharmaceutical company, validating technology and providing potential future revenue streams.Bullish3-12m0.70
    2026-08-31Novo Nordisk advances oral Wegovy and Vivani implant partnership in GLP-1 raceStrategic partnership with a major pharmaceutical company validates technology and provides potential for significant future revenue streams through milestone payments and royalties. Reduces R&D risk and accelerates market access.Bullish1-5y0.70
    2026-08-31Novo Nordisk Introduces Oral Wegovy and Vivani Implant PartnershipDirect partnership with a major pharmaceutical company for a key product, validating technology and providing potential future revenue streams.Bullish1-3m0.90
    2026-08-30Novo Nordisk Introduces Wegovy Pill and Partners on Long-Acting ImplantStrategic partnership, validation of technology, potential for milestone payments and royalties.Bullish3-12m0.70
    2026-08-30Novo Nordisk Deploys Oral Wegovy and Vivani Implant Delivery in GLP-1 RaceValidation of technology, potential for significant licensing revenue, and increased visibility.Bullish3-12m0.90
    2026-08-30Novo Nordisk Launches Oral Wegovy and Partners with Vivani for GLP-1 ImplantsStrategic partnership with a major pharmaceutical company for product development and potential commercialization, validating technology and providing funding.Bullish3-12m0.90
    2026-08-30Novo Nordisk Deploys Oral Wegovy and Vivani Delivery PartnershipDirect partnership with a major pharmaceutical company (Novo Nordisk) for a high-value drug (Wegovy). This validates VANI's technology and provides potential for significant future revenue streams.Bullish3-12m0.90
    2026-08-30Novo Nordisk Launches Oral Wegovy and Partners with Vivani on Implant DeliveryStrategic partnership with a leading pharmaceutical company, potential for significant milestone payments and royalties.Bullish1-5y0.70
    2026-08-30Novo Nordisk Introduces Oral Wegovy and Partners with Vivani on GLP-1 ImplantValidation of proprietary drug delivery technology, potential for significant milestone payments and royalties from a major pharmaceutical partner, and accelerated development pathway.Bullish1-5y0.90

    Continue this research

    Build your Vivani Medical, Inc. investment case. Continue from the evidence above, change the assumptions the developments move, and save the work to revisit as the case develops.

    This ledger is regenerated from Market Ontology's public event pipeline. View the VANI entity page →

    Research Vivani Medical, Inc. · $399/mo